摘要
The use of RNA-based next-generation sequencing(NGS)in the diagnosis and treatment of non-small cell lung cancer(NSCLC)has become an essential tool in precision medicine.This technology has revolutionized the way we approach cancer genomics,allowing for the detection of fusion genes that play a critical role in NSCLC.RNA-based NGS has been recognized by clinical practice guidelines and expert consensus as a reliable method for fusion gene detection,providing valuable insights into the underlying biology of NSCLC and guiding targeted therapies^([1,2]).
